- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
Cepheid Reports Q3 Results
Recent Articles by Benzinga Staff
- Biotech Stock Mailbag: Generex (PFE, MNKD)
- Apple Is Hoping To Have Apps For That (AAPL)
- Potential Reversals 3/19/10
- Coal Prices Ready To Burn Hot In 2010?
- Stifel Nicolaus Still Gives TriQuint A Buy (TQNT)
Company News
- Carl Icahn Makes Hostile Takeover Bid For Lions Gate Entertainment (LGF)
- Ex-Cadbury Executive To Head Kraft’s Confectionery Unit (KFT)
- Morningstar Acquires Realpoint LLC (MORN)
- Pfizer Eyes German Drug Maker Stada (PFE, TEVA)
- JPMorgan Raises Its Estimates For Intel (INTC, JPM)
Earnings
- Top Performing Industries For March 19 (CNC, HANS, CAJ, BBY, GENT)
- CTAS Well Positioned To Pursue Acquisitions
- Stocks That Created New 52-Week Highs (LOPE, HBOS, HDSN, ITMN, INET)
- Benzinga’s Volume Movers (CTEL, IPSU, HANS, TEVA, TRMB)
- Benzinga’s Top Upgrades (TTEK, ETE, CPSI)
Guidance
Posted on 10/28/09 at 4:07pm by Benzinga Staff
Cepheid (CPHD) reports Q3 EPS of ($0.13) vs ($0.12). Cepheid reports $41.6M vs $40.9M.
Cepheid guides FY9 EPS ($0.16) to ($0.13). Cepheid sees FY revenues $165M-169M versus $165.74M.
Bookmark/Search this post with:
Related Articles
Today's Trading Ideas
Featured Articles
Related News from the Stock Market
- Cepheid to Webcast Upcoming Financial Presentation
- CPHD Beats Q4 Expectations, Issues Inline Revenue Guidance For 2011
- Cepheid Reports Fourth Quarter and Full Year 2009 Results
- Cepheid Schedules 2009 Fourth Quarter and Full Year Financial Results Announcement and Webcast
- Cepheid Receives FDA Clearance for First Rapid and Accurate Surveillance Test for vanA -- the Resistance Gene Most Associated with Hospital-Acquired VRE Infections
There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.
Post new comment
Receive Benzinga's Best 2010 Stock Idea!
